A strength of this synthesis was the range of disease areas covered, which increased the number of participants whose experiences were included, allowing for generalizations across diseases. Similarly, the multidisciplinary research team ensured that the synthesis reflected a range of viewpoints, including those of consumers. A limitation was that the captured impacts and outcomes were based on self-reported behaviors, thus conclusions about behaviour change resulting from peer support interventions need to be made with caution. Yet, it is this very subjective BMS-354825 purchase reporting of the experience and impact of peer support that provides insights into the circumstances under which peer support

encourages new modes of thinking about and coping with disease. We thank the Canadian Institutes for Health Research and the Ontario Rehabilitation Research Advisory Network for financial support. NB is partially supported by the National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) CHIR-99021 molecular weight for the South West Peninsula. The views expressed in this publication are those of the authors and

not necessarily those of the National Health Service, the NIHR, or the Department of Health in England. “
“Medication safety in the elderly population represents a unique challenge. Older adults are at increased enough risk of drug side effects, drug-drug interactions and adverse events due to age-related changes and associated disease [1] and [2]. The 2012 updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults lists all drugs-to-avoid in the elderly to reduce the risk of drug-related adverse events [3] and [4]. All benzodiazepine sedative-hypnotic

drugs used for the treatment of anxiety and insomnia feature on this list due to an excessive risk of delirium, falls, fractures and motor vehicle accident [5]. With every update to the Beers criteria, significant efforts are made to inform and educate relevant parties to try and implement safer prescribing practices. We sought to develop an educational intervention to inform consumers directly about the risk of benzodiazepine drugs. We chose benzodiazepine drugs because qualitative research suggests that chronic users develop a psychological dependence to benzodiazepines, attributing them qualities that extend beyond their ordinary capacity [6]. Most consumers deny or minimize side effects while expressing subtle reluctance to outright refusal for being left suffering without these medications [6]. For these reasons physicians often express reticence for insisting on benzodiazepine discontinuation for fear of upsetting the doctor-patient relationship or because they believe that the patient tolerates the medication with minimal side effects [7].